{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:49:19Z","timestamp":1790642959388,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beha.2020.101143","type":"journal-article","created":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T11:17:52Z","timestamp":1578741472000},"page":"101143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-8681","authenticated-orcid":false,"given":"Kitsada","family":"Wudhikarn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Wills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.beha.2020.101143_bib1","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J Clin"},{"issue":"1","key":"10.1016\/j.beha.2020.101143_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.beha.2020.101143_bib3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2020.101143_bib4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1016\/j.beha.2020.101143_bib5","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.beha.2020.101143_bib6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2020.101143_bib7","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2020.101143_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101143_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8059","article-title":"Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): a multicenter, randomized, phase 3 study (APOLLO)","volume":"36","author":"Sonneveld","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2020.101143_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"issue":"Supplement_2","key":"10.1016\/j.beha.2020.101143_bib11","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-132629","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study candor (NCT03158688)","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101143_bib12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.beha.2020.101143_bib13","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"10192","key":"10.1016\/j.beha.2020.101143_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beha.2020.101143_bib15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clml.2019.02.004","article-title":"Immunotherapy in multiple myeloma: accelerating on the path to the patient","volume":"19","author":"Ghobrial","year":"2019","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2020.101143_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-019-0198-4","article-title":"Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma","volume":"9","author":"Martin","year":"2019","journal-title":"Blood Canc J"},{"issue":"25","key":"10.1016\/j.beha.2020.101143_bib17","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101143_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-02-895193","article-title":"A phase 1b study of isatuximab plus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"134","author":"Mikhael","year":"2019","journal-title":"Blood"},{"issue":"10214","key":"10.1016\/j.beha.2020.101143_bib19","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101143_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8055","article-title":"Phase III (IMROZ) study design: isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM)","volume":"36","author":"Orlowski","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2020.101143_bib21","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"f","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.beha.2020.101143_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2020.101143_bib23","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.beha.2020.101143_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.beha.2020.101143_bib25","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.beha.2020.101143_bib26","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101143_bib27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2020.101143_bib28","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2016-05-636357","article-title":"The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies","volume":"128","author":"Hoyos","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2020.101143_bib30","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.clml.2019.09.257","article-title":"MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.beha.2020.101143_bib31","unstructured":"A study of CC-99712, a BCMA antibody-drug conjugate, in Subjects with relapsed and refractory multiple myeloma. https:\/\/ClinicalTrials.gov\/show\/NCT04036461."},{"issue":"12","key":"10.1016\/j.beha.2020.101143_bib32","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.beha.2020.101143_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Canc J"},{"issue":"7","key":"10.1016\/j.beha.2020.101143_bib34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clml.2018.05.006","article-title":"Investigational antibody-drug conjugates for treatment of B-lineage malignancies","volume":"18","author":"Herrera","year":"2018","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2020.101143_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Canc J"},{"issue":"6","key":"10.1016\/j.beha.2020.101143_bib36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and\/or refractory multiple myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.beha.2020.101143_bib37","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1182\/blood.V128.22.4486.4486","article-title":"Indatuximab ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: clinical activity in patients with relapsed\/refractory multiple myeloma","volume":"128","author":"Kelly","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101143_bib38","year":"2016"},{"issue":"1","key":"10.1016\/j.beha.2020.101143_bib39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","article-title":"Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.beha.2020.101143_bib40","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"issue":"8","key":"10.1016\/j.beha.2020.101143_bib41","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.beha.2020.101143_bib42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101143_bib43","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/JCO.2018.36.15_suppl.8034","article-title":"Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma","volume":"36","author":"Buelow","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101143_bib44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood-2018-99-118425","article-title":"Anti-BCMA BiTE\u00ae AMG 701 potently induces specific T cell lysis of human multiple myeloma (MM) cells and immunomodulation in the bone marrow microenvironment","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101143_bib45","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1182\/blood-2018-99-110427","article-title":"A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-cell maturation antigen\/CD3 bispecific antibody, in patients with relapsed\/refractory advanced multiple myeloma","volume":"132","author":"Lesokhin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101143_bib46","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.beha.2020.101143_bib47","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/leu.2017.219","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2020.101143_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123924","article-title":"Monoclonal antibodies for the treatment of multiple myeloma: an update","volume":"19","author":"Abramson","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101143_bib49","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","article-title":"Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R\/R multiple myeloma (MM) patients: updated results of a first-in-human (FIH) phase I dose escalation study","volume":"37","author":"Topp","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101143_bib50","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2018-99-118970","article-title":"Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-Directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma","volume":"132","author":"Ross","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2020.101143_bib51","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1182\/blood.V128.22.4513.4513","article-title":"Trispecific antibodies for selective CD16A-directed NK-cell engagement in multiple myeloma","volume":"128","author":"Gantke","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2020.101143_bib52","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.beha.2020.101143_bib53","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"10.1016\/j.beha.2020.101143_bib54","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.beha.2020.101143_bib55","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/blood.V124.21.4727.4727","article-title":"Immunotherapy with long-lived anti-CD38 \u00d7 anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human myeloma cell lines and CD38+ cells in monkeys: a potential therapy for multiple myeloma","volume":"124","author":"Chu","year":"2014","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101143_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3132","article-title":"Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed\/refractory multiple myeloma","volume":"36","author":"Richter","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2020.101143_bib57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nature Cancer"},{"issue":"5","key":"10.1016\/j.beha.2020.101143_bib58","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2005-05-2177","article-title":"A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo","volume":"107","author":"von Strandmann","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2020.101143_bib59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/cas.12631","article-title":"Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci"},{"issue":"22","key":"10.1016\/j.beha.2020.101143_bib60","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1182\/blood.V128.22.4475.4475","article-title":"Anti-FcRH5\/CD3 T cell dependent bispecific antibody (TDB) for the treatment of multiple myeloma","volume":"128","author":"Li","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101143_bib61","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fimmu.2014.00137","article-title":"Immunophenotype of normal and myelomatous plasma-cell subsets","volume":"5","author":"Robillard","year":"2014","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101143_bib62","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2018-99-109769","volume":"132","author":"Topp","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2020.101143_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.beha.2020.101143_bib64","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2015-07-659490","article-title":"Myeloma escape from immunity: an \"inside\" job","volume":"126","author":"Rapoport","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2020.101143_bib65","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101143_bib66","author":"Braunstein"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:08Z","timestamp":1761498368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692620300049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1521692620300049"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101143","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101143"}}